The Meta Analysis And Systematic Evaluation Of Compound Sophora Injection For Three Different Tumors

Objective:Take systematic review on the clinical efficacy and security of Compound Sophora Injection for Non-small Cell Lung Cancer,Gastrointestinal tumors and Liver cancer.Methods:Using computer to retrieve CNKI, Wan Fang Database and VIP database,and collect literatures of RCT about Compound Sophora Injection for Non-small Cell Lung Cancer,Gastrointestinal tumors and Liver cancer. Filterring out qualified literature and take systematic review on those qualified literature by Rev Man4.2.2.Results : At first part, 520 literatures were retrieved, there are 26 eligible RCT literatures were included(2152 patients). The results of meta-analysis show that Compound Sophora Injection Added to Chemotherapy is better than the Chemotherapy in effectiveness[OR=1.58,95%CI(1.33,1.88),P<0.00001], quality of Life[OR=2.71,95%CI(2.15,3.41),P<0.00001] and pain relief[OR=2.94,95%CI(2.10,4.11),P < 0.00001]. At the same time, the combined group in reducing adverse reactions in patients with better performance, for example, Leukopenia rate[RR=0.31,95%CI(0.25,0.40),P<0.00001], Gastrointestinal reactions[OR=0.37,95%CI(0.29,0.48),P<0.00001]and the incidence of alopecia[OR=0.50,95%CI(0.33,0.77),P<0.00001].The second part, 478 literatures were retrieved, there are 26 eligible RCT literatures were included(2170 patients). The results of meta-analysis show that the treatment group is better than the control group in the recent effectiveness[OR=2.14,95%CI(1.79,2.57),P<0.00001] and quality of Life[OR=2.75,95%CI(2.18,3.47),P<0.00001]. At the same time, the combined group in reducing adverse reactions in patients with better performance, for example, Gastrointestinal reactions[OR=0.39,95%CI(0.31,0.49),P<0.00001], liver dysfunction[OR=0.27,95%CI(0.19,0.38),P<0.00001], leukocyte decrease[OR=0.31,95%CI(0.25,0.39),P<0.00001] and thrombocytopenia[OR=0.35,95%CI(0.25,0.50),P<0.00001].The third part, 435 literatures were retrieved, there are 24 eligible RCT literatures were included(1772 patients). The results of meta-analysis show that the treatment group is better than the control group in the recent effectiveness[OR=1.77,95%CI(1.43,2.20),P<0.00001], quality of Life[OR=2.84,95%CI(2.16,3.75),P<0.00001] and Pain relief rate[OR=3.14,95%CI(2.12,4.64),P<0.00001]. At the same time, the combinedgroup in reducing adverse reactions in patients with better performance, for example,,Gastrointestinal reactions[OR = 0.50, 95 % CI( 0.35, 0.71), P=0.0001], liver dysfunction[OR=0.44,95%CI(0.27,0.72),P=0.0009], The incidence of fever[OR=0.26,95%CI(0.17,0.41),P<0.00001] and the incidence of bellyache[OR=0.22,95%CI(0.13,0.35),P<0.00001].Conclusion : If we use Compound Sophora Injection when we treat NSCLC,Gastroenteric tumor and liver cancer, it can improve the efficiency and the quality of life, relieve pain,aiso can reduce the side effects. But the literatures are not to much,the quality of literature is low and there is publication bias.So these conclusions are for reference only, still need to carry out a large sample of high-quality randomized clinical trials to be confirmed.